As presented at the ESMO Congress 2025, in the single-arm phase 2 IKF/AIO PHERFLOT trial, the perioperative combination of FLOT chemotherapy with anti-PD-1 and anti-HER2 monoclonal antibodies led to a pathological complete response rate of 48.4% in patients with resectable HER2+ esophagogastric adenocarcinoma, meeting the prespecified co-primary endpoint. The gene discussed is ERBB2; the disease is gastroesophageal junction adenocarcinoma.